Abstract:Malaria is one of the major infectious diseases in the world.Approximately 300 -500 million people are infected and 1 -3 million deaths occur annually 1 .The multidrug resistance of the parasite and limitations with existing drugs (e.g., toxicity, side effects, high cost) 2 emphasize the urgent need for new drugs, ideally directed against potential new targets such as plasmodial proteases.These proteases are multifunctional: During the merozoite stage of the parasite they facilitate erythrocyte escape and subsequent reinvasion.In the trophozoite stage these enzymes are critical for the degradation of hemoglobin 3 .The falcipains are cysteine proteases belonging to the papain family (C1A).The best-studied members of this group are falcipains-1, -2 and -3.Falcipain-2 and -3 degrade hemoglobin at acidic pH.In addition, falcipain-2 degrades cytoskeletal proteins at neutral pH and thus facilitates the release of the mature merozoites.There is experimental evidence that cysteine protease inhibitors such as E-64, fluoromethyl ketones or aziridine derivatives inhibit falcipain-2 at low micromolar concentrations, and thereby block the development of the parasite 4,5 .However, a falcipain-specific inhibitor with in-vivo activity remains to be developed.It is expected that the elucidation of the structure of falcipain-2 will open new avenues for the development of antimalarial drugs with lowered toxicity and drug resistance.Towards this goal, we have crystallized recombinant falcipain-2 and determined its structure to ∼ 3.1 Å resolution.There are two major structural differences between papain and falcipain-2.First, the presence of a ∼ 20-residue N-terminal extension which is necessary for the proper folding of the mature protein 6 .Interestingly, this sequence element is functionally conserved within the plasmodial cysteine proteases 6 .Second, falcipain-2 contains a rather unique structural motif responsible for the binding of its natural substrate, hemoglobin 7 : a beta-hairpin located between the active-site residues His174 and Asn204 where it protrudes out of the core of the enzyme.On the basis of our results, we will discuss the interaction between falcipain and its substrate, hemoglobin.Additional experimental data on substrate binding and specificity will be presented.

Structure-Function of Falcipains: Malarial Cysteine Proteases

Towards A Functional Mapping of the Blm Helicase

Understanding the complex formation of falstatin; an endogenous macromolecular inhibitor of falcipains

The complex of Plasmodium falciparum falcipain-2 protease with an (E)-chalcone-based inhibitor highlights a novel, small, molecule-binding site

Inhibition of falcilysin from Plasmodium falciparum by interference with its closed-to-open dynamic transition

Plasmodium falciparum cysteine protease Falcipain 3: A potential enzyme for proteolytic processing of histone acetyltransferase PfGCN5

Structural Features Of Falcipain-3 Inhibitors: An In Silico Study

Expression of cysteine proteinases and cystatins in parasites and use of cysteine proteinase inhibitors in parasitic diseases. Part III: Protozoa (2): Plasmodium spp.

2-(3,4-Dihydro-4-oxothieno[2,3-d]pyrimidin-2-ylthio) Acetamides As a New Class of Falcipain-2 Inhibitors. 3. Design, Synthesis and Biological Evaluation

Pyrido[1,2-a]pyrimidin-4-ones As Antiplasmodial Falcipain-2 Inhibitors

Peptidomimetic Nitriles As Selective Inhibitors for the Malarial Cysteine Protease Falcipain-2

Profiling the Structural Determinants of Heteroarylnitrile Scaffold-Based Derivatives As Falcipain-2 Inhibitors by in Silico Methods

Cloning and characterization of Plasmodium falciparum cysteine protease, falcipain-2B.

Inhibitor of Cysteine Protease of Plasmodium malariae Regulates Malapains, Endogenous Cysteine Proteases of the Parasite

2-Amido-3-(1h-indol-3-yl)-n-substitued-propanamides As a New Class of Falcipain-2 Inhibitors. 1. Design, Synthesis, Biological Evaluation and Binding Model Studies

Deciphering structure, function and mechanism of Plasmodium IspD homologs from their evolutionary imprints

Blocking Plasmodium falciparum Development via Dual Inhibition of Hemoglobin Degradation and the Ubiquitin Proteasome System by MG132

BDA-410: a novel synthetic calpain inhibitor active against blood stage malaria.

In silico investigation of falcipain-2 inhibition by hybrid benzimidazole-thiosemicarbazone antiplasmodial agents: A molecular docking, molecular dynamics simulation, and kinetics study

Antimalarial Drugs and Drug Targets Specific to Fatty Acid Metabolic Pathway of Plasmodium falciparum

Dietary Flavonoids Fisetin and Myricetin: Dual Inhibitors of Plasmodium Falciparum Falcipain-2 and Plasmepsin II.